These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 25936312

  • 1. The impact of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a): Objectives and methods of a randomised controlled trial.
    Khan TZ, Pottle A, Pennell DJ, Barbir MS.
    Atheroscler Suppl; 2015 May; 18():103-8. PubMed ID: 25936312
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes.
    Hohenstein B, Julius U, Lansberg P, Jaeger B, Mellwig KP, Weiss N, Graehlert X, Roeder I, Ramlow W.
    Atheroscler Suppl; 2017 Nov; 30():180-186. PubMed ID: 29096835
    [Abstract] [Full Text] [Related]

  • 4. Specific Lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels.
    Ezhov MV, Safarova MS, Afanasieva OI, Pogorelova OA, Tripoten MI, Adamova IY, Konovalov GA, Balakhonova TV, Pokrovsky SN.
    Atheroscler Suppl; 2015 May; 18():163-9. PubMed ID: 25936321
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Impact of lipoprotein apheresis on thrombotic parameters in patients with refractory angina and raised lipoprotein(a): Findings from a randomized controlled cross-over trial.
    Khan TZ, Gorog DA, Arachchillage DJ, Ahnström J, Rhodes S, Donovan J, Banya W, Pottle A, Barbir M, Pennell DJ.
    J Clin Lipidol; 2019 May; 13(5):788-796. PubMed ID: 31353231
    [Abstract] [Full Text] [Related]

  • 8. Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run.
    Groß E, Hohenstein B, Julius U.
    Atheroscler Suppl; 2015 May; 18():226-32. PubMed ID: 25936330
    [Abstract] [Full Text] [Related]

  • 9. Lipoprotein apheresis - Shortening of treatment intervals reduces cardiovascular events: Case reports.
    Berent T, Berent R, Sinzinger H.
    Atheroscler Suppl; 2019 Dec; 40():125-130. PubMed ID: 31818444
    [Abstract] [Full Text] [Related]

  • 10. Lipoprotein(a)--An independent causal risk factor for cardiovascular disease and current therapeutic options.
    Kassner U, Schlabs T, Rosada A, Steinhagen-Thiessen E.
    Atheroscler Suppl; 2015 May; 18():263-7. PubMed ID: 25936335
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern.
    von Dryander M, Fischer S, Passauer J, Müller G, Bornstein SR, Julius U.
    Atheroscler Suppl; 2013 Jan; 14(1):39-44. PubMed ID: 23357139
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - A multicenter observational study.
    Schatz U, Tselmin S, Müller G, Julius U, Hohenstein B, Fischer S, Bornstein SR.
    Atheroscler Suppl; 2017 Nov; 30():246-252. PubMed ID: 29096845
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines.
    Klingel R, Heibges A, Fassbender C, Pro(a)LiFe-Study Group.
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):38-43. PubMed ID: 28185214
    [Abstract] [Full Text] [Related]

  • 19. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.
    Heigl F, Hettich R, Lotz N, Reeg H, Pflederer T, Osterkorn D, Osterkorn K, Klingel R.
    Atheroscler Suppl; 2015 May; 18():154-62. PubMed ID: 25936320
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.